Nuodil (Tiotropium)

Tiotropium is a bronchodilator that works within the airway smooth‑muscle pathway to provide long‑lasting relief in obstructive lung disease.

• Chronic obstructive pulmonary disease (COPD): improves airflow and reduces exacerbations.
• Asthma (as add‑on therapy): enhances control when inhaled corticosteroids are insufficient.
• Chronic bronchitis: decreases symptom burden and improves exercise tolerance.

• Tiotropium selectively blocks muscarinic M3 receptors on airway smooth‑muscle cells, preventing acetylcholine‑induced bronchoconstriction. This antagonism produces sustained bronchodilation, improves airway calibre, and reduces mucus secretion, supporting easier breathing over 24 hours after inhalation.

Adverse reactions to inhaled tiotropium are generally mild to moderate and vary with individual sensitivity.

Common Side Effects

• Dry mouth: mild dryness of the oral cavity.
• Cough: transient irritation after inhalation.
• Throat irritation: mild soreness or tickle.
• Upper respiratory tract infection: occasional viral‑like symptoms.
• Headache: mild, self‑limiting.
• Constipation: occasional bowel habit change.

Serious or Rare Side Effects

• Paradoxical bronchospasm: sudden worsening of breathing.
• Angioedema: swelling of lips, tongue or airway.
• Severe allergic reaction: rash, hives, or anaphylaxis.
• Urinary retention: difficulty emptying the bladder.
• Tachycardia: rapid heart rate not related to other causes.

Before initiating therapy, clinicians should evaluate patient history and comorbid conditions.

• Assess renal function: dose adjustment may be required in severe impairment.
• Review cardiovascular status: monitor for tachycardia or arrhythmias.
• Check for urinary tract obstruction: risk of retention may increase.
• Evaluate for hypersensitivity: avoid if known allergy to tiotropium or excipients.
• Store at below 25°C: keep in the original packaging, protect from moisture and heat.

Tiotropium has a limited interaction profile, but certain drugs may modify its safety or efficacy.

Major Interactions (Avoid)

• Anticholinergic overload: concurrent use with other long‑acting antimuscarinics may increase systemic anticholinergic effects.
• Beta‑agonist overuse: high‑dose LABA combined with tiotropium can heighten cardiovascular risk.

Moderate Interactions (Monitor Closely)

• Diuretics: may exacerbate dry mouth and urinary retention.
• Potassium‑sparing diuretics: monitor serum potassium if combined with inhaled corticosteroids.
• CYP3A4 inhibitors: rare metabolic interaction, observe for increased systemic exposure.